Artificial Intelligence (AI) is no longer confined to the tech sector; it is being aggressively integrated across all industries, from defense to food processing, with healthcare being no exception. Over the past couple of years, AI integration in the U.S. healthcare industry has increased manifold. According to an IDC report commissioned by Microsoft and released in March 2024, 79% of healthcare organizations were already utilizing AI technology.This rapid integration has been evident through strategic par ...

Key Takeaways Novartis lifted its 2024-2029 sales outlook to 6% and projects 5-6% annual growth through 2030.Stronger guidance reflects momentum from key drugs and recent launches despite U.S. generics.Kisqali and Scemblix saw sharp third-quarter sales jumps, prompting higher peak-sales forecasts.Novartis (NVS) recently held an investor event, wherein management projected sales to grow at a compounded annual growth rate (CAGR) of 5-6% (at constant currencies) for 2025-2030.Management also upgraded its sales ...

Key Takeaways AstraZeneca gained FDA approval to extend Koselugo use to adult NF1 patients with symptomatic, inoperable PN.Koselugo's label was also recently expanded in the EU, Japan and other countries, with more reviews ongoing.AZN's KOMET study showed a 20% overall response rate for Koselugo versus 5% with placebo by cycle 16.AstraZeneca (AZN) announced that the FDA has approved its oral, selective MEK inhibitor, Koselugo (selumetinib), for expanded use. The drug is now indicated to treat symptomatic, i ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.A more than 35% rally in the company’s stock this year has largely been driven by the explosive growth of the weight-loss drug market.Once seen as a niche category, obesity treatments are now one of the most lucrative segments in healthcare, with steadily rising demand. 4 Since the launch of Zepbound in late 2023, Lill ...

Healthcare stocks have risen this month while tech stocks have weighed on the broader market. Spencer Platt / Getty Images Why This Is Important On Wall Street, healthcare is often seen as a defensive sector that investors turn to when uncertainty is high or the economy is on the ropes. Concerns about overvalued tech stocks and have chipped away at investors' risk appetite of late, boosting healthcare in the process. The latter's shares have risen more than 20% this month, and on Friday the maker of the blo ...

Weight-loss drugmaker Eli Lilly hit a $1 trillion market cap, joining a select group of mostly tech companies https://t.co/ftoN00Qckm ...

Eli Lilly crossed into historic territory on Friday, becoming the first healthcare company ever to hit a $1 trillion market valuation. Shares rose 1.7% to mark the milestone, cementing the Indianapoli... ...

Eli Lilly briefly crossed the $1 trillion market cap threshold, the first drug maker to ever reach that milestone. ...

[You may also click here for additional information] NEW YORK, Nov. 21, 2025 /PRNewswire/ --Â Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) F ...

Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies. ...